Vanguard Capital Management
INBX icon

Vanguard Capital Management’s Inhibrx INBX Stock Holding History

Vanguard Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.7M Buy
492,477
+6,055
+1% +$607K ﹤0.01% 1982
2026
Q1 		$32.7M Buy
+486,422
New +$36.1M ﹤0.01% 2077

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management's INBX Position: Q2 2026 in Review

Vanguard Capital Management increased its Inhibrx (INBX) stake by 1.2% in Q2 2026, buying an estimated $607K and bringing the position to 492,477 shares worth $46.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Vanguard Capital Management first reported a position in INBX in Q1 2026 and has held it in 2 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Vanguard Capital Management held 492,477 shares of Inhibrx worth $46.7M as of Q2 2026.
  • Vanguard Capital Management bought 6,055 Inhibrx shares in Q2 2026, an estimated $607K.
  • Inhibrx made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1982 holding.
  • Vanguard Capital Management first reported a position in Inhibrx in Q1 2026 and has held it in 2 quarters since.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.